Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Immunogenicitet, sikkerhed, reaktogenicitet og persistens af en undersøgelsesvaccine til respiratorisk syncytialvirus (RSV) hos voksne i alderen 60 år og derover

25. september 2026 opdateret af: GlaxoSmithKline

En fase 3, randomiseret, åben, multi-lande undersøgelse til evaluering af immunogeniciteten, sikkerheden, reaktogeniciteten og persistensen af ​​en enkelt dosis af RSVPreF3 OA undersøgelsesvaccinen og forskellige revaccinationsplaner hos voksne i alderen 60 år og derover

The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1720

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Espoo, Finland, 02230
        • GSK Investigational Site
      • Helsinki, Finland, 00100
        • GSK Investigational Site
      • Helsinki, Finland, 00930
        • GSK Investigational Site
      • Jarvenpaa, Finland, 04400
        • GSK Investigational Site
      • Kokkola, Finland, 67100
        • GSK Investigational Site
      • Oulu, Finland, 90220
        • GSK Investigational Site
      • Seinäjoki, Finland, 60100
        • GSK Investigational Site
      • Tampere, Finland, 33100
        • GSK Investigational Site
      • Turku, Finland, 20520
        • GSK Investigational Site
    • Satakunta
      • Pori, Satakunta, Finland, 28100
        • GSK Investigational Site
    • Alabama
      • Mobile, Alabama, Forenede Stater, 36608
        • GSK Investigational Site
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85020
        • GSK Investigational Site
    • California
      • Riverside, California, Forenede Stater, 92503
        • GSK Investigational Site
      • San Diego, California, Forenede Stater, 92103
        • GSK Investigational Site
    • Florida
      • Coral Gables, Florida, Forenede Stater, 33134
        • GSK Investigational Site
      • Fort Myers, Florida, Forenede Stater, 33912-4316
        • GSK Investigational Site
      • Sarasota, Florida, Forenede Stater, 34243
        • GSK Investigational Site
      • The Villages, Florida, Forenede Stater, 32162
        • GSK Investigational Site
    • Indiana
      • Evansville, Indiana, Forenede Stater, 47714
        • GSK Investigational Site
    • Kansas
      • Wichita, Kansas, Forenede Stater, 67226
        • GSK Investigational Site
    • Minnesota
      • Richfield, Minnesota, Forenede Stater, 55423
        • GSK Investigational Site
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64114-4859
        • GSK Investigational Site
    • New York
      • Rochester, New York, Forenede Stater, 14609-3173
        • GSK Investigational Site
    • South Carolina
      • Mt. Pleasant, South Carolina, Forenede Stater, 29464
        • GSK Investigational Site
      • Spartanburg, South Carolina, Forenede Stater, 29303
        • GSK Investigational Site
    • Texas
      • San Antonio, Texas, Forenede Stater, 78229-6306
        • GSK Investigational Site
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23502
        • GSK Investigational Site
    • Washington
      • Wenatchee, Washington, Forenede Stater, 98801-2028
        • GSK Investigational Site
      • Fukuoka, Japan, 812-0025
        • GSK Investigational Site
      • Kumamoto, Japan, 861-4157
        • GSK Investigational Site
      • Tokyo, Japan, 160-0017
        • GSK Investigational Site
      • Changhua, Taiwan, 500
        • GSK Investigational Site
      • Taichung, Taiwan, 40447
        • GSK Investigational Site
      • Taichung, Taiwan, 407
        • GSK Investigational Site
      • Taipei, Taiwan, 100
        • GSK Investigational Site
      • Taipei, Taiwan, 104
        • GSK Investigational Site
      • Taipei, Taiwan, 112
        • GSK Investigational Site
      • Taoyuan, Taiwan, 333
        • GSK Investigational Site
      • Essen, Tyskland, 45355
        • GSK Investigational Site
      • Hamburg, Tyskland, 20095
        • GSK Investigational Site
      • Mainz, Tyskland, 55116
        • GSK Investigational Site
      • München, Tyskland, 80339
        • GSK Investigational Site
      • Wallerfing, Tyskland, 94574
        • GSK Investigational Site
      • Würzburg, Tyskland, 97074
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Tyskland, 45359
        • GSK Investigational Site
      • Goch, North Rhine-Westphalia, Tyskland, 47574
        • GSK Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

60 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female participants ≥60 YOA at first vaccination, who live in the community (CD participants) or in a Long-term care facility (LTCF participants).
  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed informed consent obtained from the participant prior to performance of any study specific procedure.
  • Participants who are medically stable in the opinion of the investigator at the time of first vaccination. Patients with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.

Exclusion Criteria:

Medical conditions

  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
  • Hypersensitivity to latex.
  • Serious or unstable chronic illness.
  • Recurrent or un-controlled neurological disorders or seizures. Participants with medically-controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.

Prior/Concomitant therapy

  • Use of any investigational or non-registered product other than the study vaccine during the period beginning 30 days before the first dose of study vaccine, or planned use during the study period.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before each dose and ending 30 days after each dose of study vaccine administration, with the exception of inactivated, split virion and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after each study vaccination.
  • Previous vaccination with an RSV vaccine.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the first dose of study vaccine or planned administration during the study period.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first vaccine dose or planned administration during the study period. For corticosteroids, this will mean prednisone >=20 mg/day, or equivalent. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product.

Other exclusions

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Bedridden participants.
  • Planned move during the study period that will prohibit participation in the trial until the study end. This includes:
  • Planned move during the study period to another LTCF that will prohibit participation in the trial until study end.
  • Planned move from the community to a LTCF that will prohibit participation in the trial until study end.
  • Participation of any study personnel or their immediate dependants, family, or household members.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: RSV_annual Group

Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 12 months post-Dose 1 and at 24 months post-Dose 1, respectively and are followed up until Month 60.

RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

Eksperimentel: RSV_Flexible revaccination Group

Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 24 months post-Dose 1 and at 48 months post-Dose 1, respectively and are followed up until Month 60.

RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

Eksperimentel: RSV_1dose Group

Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until Month 36. At Month 36, participants in this group will be re-randomized in 2 groups: RSV_1dose_M36 (which will receive 1 additional revaccination dose at Month 36 and will be followed up until Month 60) and RSV_1dose_Flexible (which will receive 1 additional revaccination dose at Month 60, and will be followed up until study end at Month 72).

RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1
Tidsramme: At Day 1

RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Day 1
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31
Tidsramme: At Day 31

RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

At Day 31
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6
Tidsramme: At Month 6

RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

At Month 6
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12
Tidsramme: At Month 12

RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

At Month 12
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1
Tidsramme: At Day 1

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

At Day 1
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31
Tidsramme: At Day 31

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

At Day 31
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6
Tidsramme: At Month 6

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

At Month 6
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12
Tidsramme: At Month 12

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

At Month 12

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Humoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 1
Tidsramme: At Day 1

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by enzyme-linked immunosorbent assay (ELISA). The corresponding antibody GMC was expressed in Elisa Laboratory Units/milliliter (ELU/mL).

At Day 1
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 31
Tidsramme: At Day 31

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Day 31
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 6
Tidsramme: At Month 6

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 6
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 12
Tidsramme: At Month 12

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 12
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 18
Tidsramme: At Month 18

Month 18 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 18
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 24
Tidsramme: At Month 24

Month 24 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 24
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 30
Tidsramme: At Month 30

Month 30 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 30
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 36
Tidsramme: At Month 36

Month 36 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 36
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 13
Tidsramme: At Month 13

Month 13 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 13
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 25
Tidsramme: At Month 25

Month 25 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 25
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 18
Tidsramme: At Month 18

Month 18 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 18
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 24
Tidsramme: At Month 24

Month 24 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 24
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 30
Tidsramme: At Month 30

Month 30 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 30
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 36
Tidsramme: At Month 36

Month 36 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 36
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 13
Tidsramme: At Month 13

Month 13 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 13
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 25
Tidsramme: At Month 25

Month 25 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 25
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 18
Tidsramme: At Month 18

Month 18 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 18
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 24
Tidsramme: At Month 24

Month 24 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 24
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 30
Tidsramme: At Month 30

Month 30 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 30
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 36
Tidsramme: At Month 36

Month 36 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 36
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 13
Tidsramme: At Month 13

Month 13 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 13
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 25
Tidsramme: At Month 25

Month 25 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 25
Cell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1
Tidsramme: At Day 1

Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Day 1
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1
Tidsramme: At Day 1

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Day 1
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31
Tidsramme: At Day 31

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Day 31
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31
Tidsramme: At Day 31

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Day 31
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6
Tidsramme: At Month 6

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 6
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6
Tidsramme: At Month 6

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 6
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12
Tidsramme: At Month 12

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 12
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12
Tidsramme: At Month 12

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 12
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18
Tidsramme: At Month 18

Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 18
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18
Tidsramme: At Month 18

Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 18
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24
Tidsramme: At Month 24

Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 24
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24
Tidsramme: At Month 24

Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 24
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30
Tidsramme: At Month 30

Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 30
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30
Tidsramme: At Month 30

Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 30
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36
Tidsramme: At Month 36

Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 36
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36
Tidsramme: At Month 36

Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 36
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13
Tidsramme: At Month 13

Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 13
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13
Tidsramme: At Month 13

Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 13
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25
Tidsramme: At Month 25

Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 25
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25
Tidsramme: At Month 25

Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 25
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Day 1
Tidsramme: During the 4-day follow up period after first vaccination (vaccine administered on Day 1)

The solicited administration-site events were erythema, pain and swelling at the injection site.

During the 4-day follow up period after first vaccination (vaccine administered on Day 1)
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 12
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Month 12 to Month 18 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.

During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 24
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Month 24 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.

During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Day 1
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered on Day 1)

The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius [°C]), headache and myalgia.

During the 4-day follow up period after vaccination (vaccine administered on Day 1)
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 12
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Month 12 to Month 18 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0°C), headache and myalgia.

During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 24
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Month 24 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius (°C)), headache and myalgia.

During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 1
Tidsramme: During the 30-day follow up period after vaccination (vaccine administered on Day 1)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

During the 30-day follow up period after vaccination (vaccine administered on Day 1)
Number of Participants With Any Unsolicited AEs Following Vaccination at Month 12
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Month 12 to Month 18 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With Any Unsolicited AEs Following Vaccination at Month 24
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Month 24 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1
Tidsramme: From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
Number of Participants With SAEs Following Vaccination at Month 12
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Month 12 to Month 18 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With SAEs Following Vaccination at Month 24
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Month 24 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1
Tidsramme: From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)

pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
Number of Participants Reporting Any pIMD Following Vaccination at Month 12
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Month 12 to Month 18 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants Reporting Any pIMD Following Vaccination at Month 24
Tidsramme: During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Month 24 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With a Fatal SAE, Related SAE and Related pIMDs
Tidsramme: From first vaccination (Day 1) up to study end (Month 36)

A fatal SAE is any untoward medical occurrence that results in death. A related SAE is an SAE considered to be causally related to the study intervention. A related pIMD is a pIMD considered to be causally related to the study intervention.

The study is ongoing at the time of the results posting. Results for Months 18 up to study end (Month 36) will be updated during final posting.

From first vaccination (Day 1) up to study end (Month 36)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. februar 2021

Primær færdiggørelse (Faktiske)

6. juni 2022

Studieafslutning (Anslået)

19. februar 2027

Datoer for studieregistrering

Først indsendt

27. januar 2021

Først indsendt, der opfyldte QC-kriterier

27. januar 2021

Først opslået (Faktiske)

1. februar 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

IPD for this study will be made available via the Clinical Study Data Request site.

IPD-delingstidsramme

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

IPD-delingsadgangskriterier

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner